Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Betting the PharmPosted: December 6, 2006Pfizer's failure to launch torcetrapib will have repercussions throughout the industry on many different levels. As a seminal event, it will rival the withdrawal of Vioxx from the market. In today's post to Pharma Marketing Blog, I discuss the littany of repercussions this has already had on Pfizer and the drug industry as well as future repercussions. It includes one surprisingly frank assessment by a business expert about the "creaky" nature of the pharmaceutical industry. It can be improved, says this author's report, if the industry focuses on strengthening its non-blockbuster pipeline and launches an immediate "diplomatic offensive" to win public opinion. Or something to that effect. For more on this, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Reprint Special Offer Communicating Risk: Let the Dialog Begin Some communications experts are calling for simplifying the communication of risk information in broadcast, print, and Internet DTC ads. FDA is looking for better ways to communicate risk. This article summarizes a Pharma Marketing Roundtable discussion on this issue and includes information about Pfizer's way of communicating risk Order and pay for this reprint now using your credit card ONLY $6.95!
|